ArticleFrontiers in oncology2021

Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women.

Eunae Jeong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.